Imaging study for advanced solid tumors
Part of Cancer, Digestive system, Lungs & breathing, Skin clinical trials.
This trial tests a new imaging agent, LNTH-2403, to see if it can help visualize tumors in people with certain advanced cancers that have not responded to standard treatments. It may help doctors decide on future treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of advanced cancer (colorectal, head and neck, lung, or triple-negative breast cancer) that has spread or cannot be removed and has not responded to standard treatments.
- You need to have had a CT or MRI scan in the last 8 weeks showing at least one area of new or remaining disease.
- You must be willing to provide a sample of your stored tumor tissue.
- You must be able to take care of yourself (ECOG performance status 0 or 1).
- You must not be pregnant and must use effective birth control during the study and for 3 months after the scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent, 64Cu-LNTH-1363S, to see if it can find certain sarcomas and gastrointestinal cancers. The goal is to help doctors better see where your cancer is and plan the best treatment. You may be eligible if you have a sarcoma or a GI cancer and are willing to have a tumor tissue sample taken.
This early-stage study tests two different imaging (scanning) methods to better detect head and neck cancer. Your results from the scans may help doctors see where disease is before standard surgery to remove lymph nodes in the neck.
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
This study tests an experimental drug called CT3001 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it's safe and effective, and for some patients with colorectal cancer, it may be combined with standard chemotherapy.
This study checks how well the LUM Imaging System can detect cancers of the esophagus, colon, or pancreas during the time you are preparing for surgery. It’s mainly meant to see if the scan works safely and clearly for doctors to find cancer areas.
This trial tests a new drug called LNF2105 in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called Nectin-4 found on many cancer cells, and researchers want to see if LNF2105 can help shrink or control these tumors.
Hear when a new Imaging trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.